相关临床试验
269
27 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1821
进行中（未招募）
9
3.4%
已完成
113
42.0%
Enrolling By Invitation
1
0.4%
No Longer Available
1
0.4%
尚未招募
17
6.3%
招募中
40
14.9%
暂停
1
0.4%
终止
9
3.4%
Unknown
69
25.6%
撤回
9
3.4%
暂无批准数据
- Demand for medical evacuation and repatriation to Singapore is rising, with SGH reporting 80 cases in 2024-2025 compared to 50 in 2023, and TTSH receiving over 60 queries in 2025. - Medical evacuation costs can exceed $100,000 per case, with insurers like MSIG Singapore and Great Eastern offering coverage up to $1 million, though pre-existing conditions often require extra premiums. - Evacuation timelines depend on patient stability and logistical factors including aircraft availability, flight permits, and visas; medical flights take longer than commercial flights due to refuelling needs. - Public hospitals including TTSH and SGH offer 24/7 patient liaison services to coordinate overseas medical transfers and provide live updates until the patient reaches Singapore.
- Singapore will commence clinical trials of histotripsy, a non-invasive ultrasound-based cancer treatment that uses microbubbles to destroy tumors without surgery or radiation, starting in the second half of 2025. - The Li Ka Shing Foundation and Temasek Trust have committed S$12 million to bring two histotripsy machines to Singapore, with initial trials focusing on 40 liver cancer patients before expanding to kidney and pancreatic cancers. - Histotripsy, which received FDA approval for liver tumors in October 2023, has already treated approximately 50 cancer patients in Hong Kong and over 1,000 in the US, with researchers noting its potential to stimulate immune responses against non-targeted tumors.
- Singapore researchers have launched the BEXMET clinical trial to test Bexarotene's ability to convert aggressive triple-negative breast cancer cells into less aggressive states, making them more responsive to chemotherapy. - The novel approach uses the retinoid drug Bexarotene to induce mesenchymal-to-epithelial transition, potentially offering a cost-effective treatment strategy for this aggressive cancer subtype. - Preclinical studies showed that converting cancer cells from mesenchymal to epithelial states resulted in longer-lasting responses and reduced cancer relapse in animal models. - The three-year trial aims to recruit 12-20 patients with metastatic TNBC and combines Bexarotene with Capecitabine chemotherapy in a novel treatment cycle.
